Vir Biotechnology, Inc.
VIR
$5.53
$0.254.74%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.37M | 2.38M | 3.08M | 56.38M | 16.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.37M | 2.38M | 3.08M | 56.38M | 16.79M |
| Cost of Revenue | 88.79M | 195.23M | 105.17M | 100.18M | 106.37M |
| Gross Profit | -76.42M | -192.85M | -102.09M | -43.81M | -89.58M |
| SG&A Expenses | 26.70M | 25.74M | 30.27M | 36.27M | 41.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.49M | 220.97M | 135.43M | 136.46M | 147.59M |
| Operating Income | -103.12M | -218.59M | -132.36M | -80.08M | -130.80M |
| Income Before Tax | -104.68M | -213.54M | -139.89M | -65.00M | -120.76M |
| Income Tax Expenses | -86.00K | 177.00K | -1.51M | 276.00K | -4.78M |
| Earnings from Continuing Operations | -104.59M | -213.72M | -138.38M | -65.28M | -115.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 0.00 |
| Net Income | -104.59M | -213.72M | -138.38M | -65.28M | -115.97M |
| EBIT | -103.12M | -218.59M | -132.36M | -80.08M | -130.80M |
| EBITDA | -100.23M | -215.70M | -128.10M | -75.56M | -126.32M |
| EPS Basic | -0.76 | -1.56 | -1.02 | -0.48 | -0.86 |
| Normalized Basic EPS | -0.41 | -0.92 | -0.52 | -0.27 | -0.52 |
| EPS Diluted | -0.76 | -1.56 | -1.02 | -0.48 | -0.87 |
| Normalized Diluted EPS | -0.41 | -0.92 | -0.52 | -0.27 | -0.52 |
| Average Basic Shares Outstanding | 136.81M | 136.65M | 136.23M | 135.28M | 134.61M |
| Average Diluted Shares Outstanding | 136.81M | 136.65M | 136.23M | 135.28M | 134.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
